...
Why us? Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • Non-NHS: Private healthcare provider only. Pricing varies by treatment and site. Availability varies by clinical location.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

Author Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making.

MD MRCGP DFFP
Was this answer helpful?
Authored and medically reviewed by Dr Farzana Khan on 6 August 2026
Rate Dr Farzana's explanation



Outcome audit


Separate domains


Evidence-aware

Women’s Health Clinic FAQ

How does real-time doppler ultrasound track changes in clitoral arterial peak systolic velocity before and after an O-Shot series?

O-Shot results should be discussed through clearly defined outcomes, because arousal, sensation, lubrication, pain and orgasm are not the same clinical endpoint.

Direct answer

The benchmark should present Doppler ultrasound as a specialist vascular assessment or research-style audit tool, not routine proof of sexual improvement. It should avoid turning peak systolic velocity changes into predictable O-Shot outcome claims.

The useful answer explains how this fits into consultation, consent and follow-up without turning the page into a self-directed protocol.


Educational only. Use this as general education before discussing your own medical history with a clinician. Results vary. Not a cure.

Women's Health Clinic consultation for How does real-time doppler ultrasound track changes in clitoral arterial peak systolic velocity before and after an O-Shot series?

O-Shot clinical review

At a glance

These points give the safe frame before assuming an O-Shot can be combined, measured, repeated or used to solve the concern.

At a glance

Clinical summary

Baseline first

Clinicians need a clear starting point before interpreting any change after treatment.

Domains differ

Desire, arousal, lubrication, orgasm, satisfaction and pain should not be merged into one success claim.

Tools have limits

FSFI, biothesiometry, algometry and Doppler findings need clinical interpretation.

No proof of causation

A score or measurement change does not automatically prove the O-Shot caused meaningful benefit.

Important safety note

Seek medical advice promptly for heavy or persistent bleeding, fever, offensive discharge, ulcers, severe pelvic or vulval pain, urinary retention, fainting, worsening swelling, neurological symptoms, suspected infection, systemic illness or unexplained genital lesions.

FSFI
Arousal
Lubrication
Pain
Audit




Detailed answer

Detailed answer

Outcome measurement is useful only when the symptom target is defined before treatment and reviewed with the same language afterwards.

Clinical context

A patient may report better lubrication but unchanged orgasm, less pain but unchanged arousal, or improved confidence without measurable vascular change.

Assessment
Consent
Safety
Evidence

What matters first

Outcome measurement is useful only when the symptom target is defined before treatment and reviewed with the same language afterwards.

Why it matters

A patient may report better lubrication but unchanged orgasm, less pain but unchanged arousal, or improved confidence without measurable vascular change.

Evidence boundary

Validated questionnaires and specialist tools can support audit, but they cannot promise response or replace a careful symptom review.

Safety boundary

If there is no meaningful change by follow-up, the answer is reassessment rather than automatic repeat treatment.

What this means in practice

A careful page gives a clinical framework without publishing a procedural script or implying predictable response.

The plan should be individualised around symptoms, tissue state, medical history, alternatives and follow-up.





Patient safety

Why this matters

This topic matters because O-Shot decisions can be distorted by marketing, urgency, embarrassment or over-simple outcome claims.

It protects consent

Patients need balanced information, space to decide and freedom from exaggerated claims.

It protects tissue

Vulval and vaginal tissue may be sensitive, inflamed, atrophic, bruised or recovering from another treatment.

It protects meaning

Arousal, lubrication, sensation, pain and orgasm should be evaluated separately.

It protects safety

Bleeding, infection, urinary symptoms, severe pain and neurological symptoms should not be dismissed.

A clinical conversation

The question is not only whether PRP is possible, but whether it is the right next step for this person.

That is why assessment, consent, realistic expectations and follow-up are central to responsible intimate PRP care.





Considerations

What to consider

Consider the symptom target, diagnosis, timing pressure, other treatments, medicines, bleeding history, infection risk, pain, urinary symptoms and expectations.

Consultation priorities

The consultation records baseline symptoms, distress, pain, dryness, arousal, orgasm, medicines, hormones, pelvic-floor symptoms and relationship context.

History
Timing
Consent
Follow-up

Assessment

The consultation records baseline symptoms, distress, pain, dryness, arousal, orgasm, medicines, hormones, pelvic-floor symptoms and relationship context.

Safety review

The clinician chooses whether a questionnaire, examination, pain mapping or specialist measurement would add useful information.

Treatment fit

At follow-up, each domain is reviewed separately so improvement is not overstated or wrongly attributed.

Review

Non-response should trigger review of diagnosis, GSM, pelvic-floor tone, vulval pain, medicines, psychological context and whether PRP was the right target.

Practical expectations

Response can be partial, delayed or absent, and published intimate PRP protocols are not uniform.

Prices, exact procedural details, treatment timing and aftercare should be confirmed with the clinic before booking.





Common concerns and myths

Common misconceptions

These myths can make timing, outcome and follow-up questions sound more certain than they are.

Myth: one score proves the O-Shot worked

Reality: scores help structure discussion but do not prove causation.

Myth: objective tests promises sexual improvement

Reality: nerve or vascular measurements do not automatically match comfort, arousal or orgasm.

Myth: no change means another injection is always needed

Reality: non-response should prompt reassessment first.

Evidence and context

Mechanism helps explain why PRP is discussed, but it does not replace diagnosis, consent or suitability checks.

Different outcomes

Comfort, arousal, lubrication, orgasm, urinary symptoms and pain are different outcomes and should not be blurred together.





Safety checklist

Safety checklist

Use these checks before assuming intimate PRP is suitable.

Is the goal clear?

Clarify whether the target is dryness, pain, arousal, sensation, urinary symptoms, timing, measurement or confidence.

Has tissue context been reviewed?

Scarring, menopause-related change, infection symptoms, urinary issues, pain and active lesions can affect suitability.

Are red flags absent?

Pause and seek clinical review for new bleeding, fever, offensive discharge, ulcers, severe pain, urinary retention, fainting, spreading swelling, neurological symptoms, systemic illness or any concern about infection.

Is uncertainty documented?

Consent should explain limited evidence, variable response and possible discomfort, bruising or bleeding.

Reassuring signs

Proceeding is more reasonable when the concern is stable, red flags are absent and expectations are realistic.

Stable
No red flags
Review plan

Reasons to pause

Pause for unstable illness, new bleeding, infection symptoms, ulcers, severe pain, urinary retention, fainting, spreading swelling or uncertainty about medicine safety.

Bleeding
Infection
Unstable illness




When to escalate

When to seek medical help

Some symptoms around intimate PRP treatment need prompt assessment.

Use NHS 111 online

Bleeding or fainting

Heavy bleeding, persistent bleeding, spreading bruising or fainting should be assessed by a clinician.

Infection symptoms

Fever, offensive discharge, worsening burning, ulcers or pelvic pain may need swabs, urine testing or review.

Unexpected reaction

Worsening swelling, severe soreness, tissue colour change, neurological symptoms or new urinary difficulty should be reviewed.

Emergency symptoms

Call 999 in a life-threatening emergency, including collapse, chest pain, breathing difficulty or sudden neurological symptoms.

Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.

More clinical detail

Why domains matter

Female sexual response is not one measurement. Desire, arousal, lubrication, pain and orgasm can move in different directions, so each needs its own review.

Why audit must stay honest

Tools can document change, but the clinical question is whether the patient has meaningful, safe and sustained improvement without another cause being missed.

Next step

Book an intimate health consultation

A consultation can clarify whether symptoms fit GSM, sexual-function concerns, pelvic-floor pain, urinary symptoms, recovery concerns or another cause, and whether PRP is suitable.

View Research Sources (12 Sources)
• O-Shot official questions
• PRP injections for female sexual dysfunction and SUI systematic review
• Female Sexual Function Index original validation
• NHS female sexual problems
• NHS pain during or after sex
• O Shot and G Shot London competitor page
• GMC decision making and consent
• ASA cosmetic interventions and advertising guidance
• NICE urinary incontinence and pelvic organ prolapse guideline
• NHS vaginal dryness
• NHS bruises
• NHS sepsis

These 12 source names are selected from 72 curated sources. Additional reviewed material included peer-reviewed clinical papers; duplicate and low-relevance records were removed before display.

Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.

  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • Non-NHS: Private healthcare provider only. Pricing varies by treatment and site. Availability varies by clinical location.